Allopurinol toxicity: its toxic organ-specificity between the liver and the kidney in the rat.

In this study, allopurinol toxicity was investigated in the liver and the kidney in the rat. Allopurinol was intraperitoneally administered to rats, once a day, for 1, 3 or 10 days, in doses of 3, 10, 30 and 100 mg/kg body weight/day. At the 24th hour after the last administration, the rat was sacrificed, and blood and tissue samples were taken for analyses. In doses of 30 mg/kg/day and more, decreases of the body weight and the liver weight were observed, while the kidney weight increased. The plasma activities of alkaline phosphatase, glutamic oxaloacetic and glutamic pyruvic transaminases showed no increases, while the blood urea nitrogen and creatinine increased. These changes were the most remarkable in the 3 day administration, whereas they approached the control level thereafter. In doses of 10 mg/kg/day and less, no significant changes were observed in comparison to the control. These results denote that the minimal toxic dose ranges between 10 and 30 mg/kg/day, and that the kidney is more sensitive than the liver. In addition, these results also denote that the renal and hepatic failures are reversively restored even when allopurinol is further administered later than the 3 day. This fact suggests not only that the capacity inactivating allopurinol in the body is increased, but also that the enzymatic induction in the allopurinol inactivation system is accelerated.

[1]  K. Ishak,et al.  Allopurinol hepatotoxicity. Report of two cases and review of the literature. , 1981, Annals of internal medicine.

[2]  B. Wexler,et al.  Allopurinol-Induced Myocardial and Renal Damage in Nonarteriosclerotic (Virgin) and Arteriosclerotic (Breeder) Sprague-Dawley Rats 1 , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[3]  R. Butler,et al.  Massive hepatic necrosis in a patient receiving allopurinol. , 1977, JAMA.

[4]  H. Selye Protection by glucocorticoids against allopurinol nephropathy. , 1972, Acta Endocrinologica.

[5]  R. Mills Severe hypersensitivity reactions associated with allopurinol. , 1971, JAMA.

[6]  G. Hitchings,et al.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. , 1966, Biochemical pharmacology.

[7]  R. Rundles,et al.  Allopurinol in the treatment of gout. , 1965, Annals of internal medicine.

[8]  A. Gutman,et al.  EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. , 1964, The American journal of medicine.

[9]  Rw Rundres Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout , 1963 .

[10]  A. L. Chaney,et al.  Modified reagents for determination of urea and ammonia. , 1962, Clinical chemistry.

[11]  S REITMAN,et al.  A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. , 1957, American journal of clinical pathology.

[12]  E. King,et al.  Estimation of Plasma Phosphatase by Determination of Hydrolysed Phenol with Amino-antipyrine , 1954, Journal of clinical pathology.

[13]  H. Taussky,et al.  ON THE COLORIMETRIC DETERMINATION OF CREATININE BY THE JAFFE REACTION , 1945 .